Health Technology · Supplementary · from Health Technology
Case 2: Telemedicine Management of Chronic Disease
Patient Presentation
Demographics: 68-year-old male retired farmer, rural community
Chief Complaint: "My blood sugars have been all over the place and I can't get to the clinic easily."
History of Present Illness: A 68-year-old male with a 15-year history of type 2 diabetes mellitus presents via telemedicine video visit from his home, which is 87 miles from the nearest endocrinology clinic. He was transitioned to telemedicine follow-up 6 months ago after his endocrinologist implemented a remote patient monitoring (RPM) program. He uses a continuous glucose monitor (CGM) that transmits data in real-time to his care team.
Review of his CGM data over the past 14 days reveals a time-in-range (70-180 mg/dL) of only 42% (target >70%), with significant postprandial hyperglycemia reaching 280-320 mg/dL after dinner and overnight hypoglycemia with glucose values dropping to 54-62 mg/dL between 2:00 AM and 4:00 AM. His most recent HbA1c was 8.9%, up from 7.8% three months ago.
During the video visit, the patient demonstrates his injection technique, which reveals he has been injecting his evening insulin into a lipohypertrophic area on his abdomen. He also reports skipping his morning metformin dose because it causes nausea, and he did not know he could take it with food to reduce GI side effects.
Past Medical History:
- Type 2 diabetes mellitus (15 years)
- Hypertension
- Diabetic peripheral neuropathy
- Chronic kidney disease stage 3a (eGFR 52 mL/min)
- Osteoarthritis of both knees
Medications:
- Insulin glargine 32 units at bedtime
- Insulin lispro 8 units before meals
- Metformin 1000 mg twice daily (admits to skipping AM dose)
- Lisinopril 20 mg daily
- Gabapentin 300 mg TID
- Aspirin 81 mg daily
Social History:
- Retired farmer, lives with wife in rural area
- Nearest pharmacy 35 miles away (uses mail-order)
- Limited broadband internet; uses cellular hotspot for telemedicine
- Former smoker (quit 10 years ago, 20 pack-year history)
Family History:
- Father: type 2 diabetes, died of MI at age 72
- Mother: hypertension, stroke at age 78
Physical Examination
- Vital Signs (patient-reported home readings): BP 148/88 mmHg, HR 76 bpm, Weight 98 kg (BMI 32.1)
- General (video assessment): Overweight male, appears well, no acute distress
- Skin (shown on camera): Lipohypertrophic nodule approximately 3 cm diameter on left lower abdomen at injection site; feet examined via camera showing intact skin, no ulcers
- Extremities: Mild bilateral lower extremity edema noted on video
Workup and Results
Laboratory Studies (drawn at local community lab 3 days prior):
| Test | Result | Reference Range |
|---|---|---|
| HbA1c | 8.9% | <7.0% (target) |
| Fasting glucose | 186 mg/dL | 70-100 mg/dL |
| Creatinine | 1.4 mg/dL | 0.7-1.3 mg/dL |
| eGFR | 52 mL/min/1.73m² | >60 mL/min/1.73m² |
| Urine albumin/creatinine ratio | 88 mg/g | <30 mg/g |
| Total cholesterol | 218 mg/dL | <200 mg/dL |
| LDL | 128 mg/dL | <100 mg/dL |
| Potassium | 4.6 mEq/L | 3.5-5.0 mEq/L |
CGM Data (14-day summary):
- Time in range (70-180 mg/dL): 42%
- Time above range (>180 mg/dL): 48%
- Time below range (<70 mg/dL): 10%
- Glucose management indicator (GMI): 8.7%
- Coefficient of variation: 41% (target <36%)
Clinical Image
Illustration of a remote patient monitoring dashboard showing CGM data trends, ambulatory glucose profile, and time-in-range statistics used for telemedicine diabetes management. Source: Educational illustration.
Diagnosis
Poorly Controlled Type 2 Diabetes Mellitus with Insulin Lipohypertrophy, Nocturnal Hypoglycemia, and Medication Non-adherence, Managed via Telemedicine with Remote Patient Monitoring
Key Diagnostic Criteria:
- HbA1c 8.9% (worsening from 7.8%)
- CGM showing time-in-range of only 42%
- Nocturnal hypoglycemia pattern (2:00-4:00 AM)
- Postprandial hyperglycemia after dinner
- Lipohypertrophy at injection site identified via video examination
- Medication non-adherence (skipping morning metformin)
Treatment Plan
- Injection site rotation: Educate patient to rotate injection sites, avoiding the lipohypertrophic area; when switching sites, reduce insulin glargine dose by 20% (to 26 units) as absorption will improve in non-lipohypertrophic tissue
- Insulin adjustment: Reduce bedtime glargine to 26 units to address nocturnal hypoglycemia; increase dinner lispro to 10 units for postprandial coverage
- Metformin adherence: Instruct to take morning metformin with breakfast to reduce GI side effects; consider switching to extended-release formulation
- Add statin: Start atorvastatin 40 mg daily for LDL >100 with diabetic nephropathy
- RPM intensification: Increase CGM data review to weekly for the next month; set up automated alerts for glucose <70 mg/dL
- Follow-up: Telemedicine visit in 2 weeks to review CGM data after changes; repeat HbA1c in 3 months
- Local coordination: Send updated care plan to patient's local primary care provider for in-person foot exam and blood pressure reassessment
Key Learning Points
- Telemedicine with remote patient monitoring can effectively manage chronic diseases in rural and underserved populations, overcoming geographic barriers
- CGM data review during telemedicine visits provides actionable glycemic pattern data that HbA1c alone cannot reveal
- Video-based physical examination, while limited, can identify important findings such as lipohypertrophy and foot abnormalities
- Insulin absorption is significantly impaired at lipohypertrophic sites, requiring dose adjustment when rotating to new sites
- Successful telemedicine chronic disease management requires integration with local laboratory and pharmacy services